LITTLE ROCK, AR (KATV) — A new form of technology that is designed to improve heart function through a tool that provides a transcatheter edge-to-edge repair approach has received approval by the Food and Drug Administration (FDA).
Abbot’s TriClip transcatheter edge-to-edge repair (TEER) system is used to treat tricuspid regurgitation (TR), which is a condition that impacts the Tricuspid valve in the heart, causing it to leak.
The innovative treatment option is minimally invasive, according to a release, and gives patients another option besides considering open-heart surgery…